Interestingly, our data show that mutation of the proline equivalent to P286 in Pol δ does not lead to hypermutation, consistent with the fact that tumour sequencing has not identified this as a clinical mutation, and also the frequency of somatic Pol δ proofreading domain mutations seems to be much lower than Pol ε mutations [18]. This evidence concerns the gene EPX and neoplasm.